IPSEN (OTCMKTS:IPSEY) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Shares of IPSEN (OTCMKTS:IPSEY) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $31.11 and traded as high as $35.12. IPSEN shares last traded at $34.73, with a volume of 354 shares.

IPSEN Stock Performance

The business has a 50-day moving average price of $33.86 and a two-hundred day moving average price of $31.11.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.